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The impact of NIH-IV prostatitis on early post-operative
outcomes of transurethral resection of the prostate in
patients with symptomatic benign prostate hyperplasia
Fatih Rüştü YALÇINKAYA1, Ahmet GÖKÇE1, Mürsel DAVARCI1, Eşref Oğuz GÜVEN1,
Mehmet İNCİ1, Süleyman Barış KARTAL2, Ali AYYILDIZ2, Mevlana Derya BALBAY1

Aim: Transurethral prostate resection (TURP) is still considered the gold standard in the treatment of symptomatic
benign prostate hyperplasia (BPH). Category IV chronic prostatitis (CP) is described by the National Institute of
Health (NIH-IV) as the asymptomatic inflammation of the prostate and it may be detected along with benign prostate
hyperplasia (BPH) during histological examinations of the prostate. In this study, we evaluate the impact of the presence
of NIH-IV defined prostatitis on early post-operative outcomes of transurethral resection of the prostate.
Materials and methods: Between 2004 and 2008, medical records of 247 patients who underwent TURP in Adana
Numune Training and Research hospital were examined, retrospectively. Patients who had a histological diagnosis of only
BPH were considered in Group 1 whereas Group 2 consisted of patients with both NIH-IV CP and BPH simultaneously.
Factors such as total prostate specific antigen (tPSA) levels, International Prostate Symptom Scores (IPSS), singlequestion quality of life (QoL) assessments, maximum flow rates (Q max), residual urine volumes, catheterization times,
re-catheterization rates, and the duration of re-catheterization were compared between these 2 groups. IPSS, QoL, and
uroflowmetry measurements were compared between the 2 groups again at the third post-operative month. Statistical
analysis with Student’s t and chi-square tests was performed with SPSS ® version 16.
Results: Preoperatively, no statistically significant difference was present between the 2 groups with respect to IPSS,
Q max, QoL, prostate volume, tPSA, and mean catheterization time (P > 0.05); however, re-catheterization rates were
significantly different (P < 0.05). While meaningful difference was found between 90th day IPSS and QoL medians (P <
0.05), there was no difference in Q max medians (P > 0.05).
Conclusion: NIH-IV chronic prostatitis shows negative effects on the subjective post-operative results and recatheterization frequency of BPH patients that have undergone TURP.
Key words: Chronic prostatitis, BPH, TURP, prostate, histology

NIH-IV kronik prostatitin semptomatik benign prostat hiperplazili hastaların
transüretral prostat rezeksiyonu sonrası erken dönem sonuçlarına etkisi
Amaç: Transüretral prostat rezeksiyonu (TURP) semptomatik benign prostat hiperplazisi (BPH) cerrahi tedavisinde
halen altın standarttır. Kronik prostatit (KP) National Institute of Health -IV (NIH-IV) prostatın asemptomatik
inflamasyonu olup histolojik örneklerde BPH ile sıkça birlikte bulunmaktadır. Bu çalışmada KP NIH-IV’ün semptomatik
BPH nedeniyle yapılan TURP’ ların post operatif erken sonuçlarına etkisini incelenmesi amaçlanmıştır.
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Yöntem ve gereç: Adana Numune Eğitim ve Araştırma Hastanesinde 2004-2008 yılları arasında TURP yapılan 247
hastanın tıbbi kayıtları retrospektif olarak incelendi. Histopatolojiye göre saf BPH olanlar 1. grubu oluştururken KP ve
BPH olanlar 2. grubu oluşturdular. Total prostat spesifik antijen seviyesi (tPSA), Uluslararası Prostat Semptom Skoru
(IPSS), tek soruluk yaşam kalitesi (QoL), maksimum akım hızı (Q max), sondalı kalma süresi, ve erken tekrar sondalama
oranları ve süreleri ile birlikte post-op 90. gündeki IPSS, QoL, Qmax değerleri karşılaştırıldı. istatistiksel analiz Student
t ve ki kare testleri ile SPSS® version 16 ile yapıldı.
Bulgular: Preoperatif IPSS, Qmax, QoL, prostat hacimleri, tPSA ve sondalı kalma süreleri ortancaları grup 1 ve 2
arasında anlamlı farklılık göstermedi (P > 0,05). Tekrar sondalama oranları arasında anlamlı farklılık vardı (P < 0,05).
Doksanıncı gün IPSS ve QoL ortancaları arasında anlamlı farklılık saptanırken (P < 0,05), Q max ortancaları arasında
farklılık yoktu (P > 0,05).
Sonuç: KP NIH-IV semptomatik BPH nedeniyle TURP yapılan hastaların subjektif post-op sonuçları ve tekrar
sondalama sıklıkları üzerinde olumsuz etki göstermektedir.
Anahtar sözcükler: Kronik prostatit, BPH, TURP, prostat, histoloji

Introduction
Benign prostate hyperplasia (BPH) is the
enlargement of the prostate as a result of the
hyperproliferation of stromal and glandular cells with
mesenchymal cell predominance. BPH is the most
common benign pathology of the prostate in the
aging male and was reported to affect 70% and 90%
of men aged 61-70 and 81-90 years, respectively (1).
BPH becomes clinically relevant when it causes lower
urinary tract symptoms (LUTS). The prevalence of
LUTS in the over-40 male population of Europe was
reported to be 30% (2).
BPH and chronic prostatitis may frequently occur
concomitantly (3,4). Although BPH was the cause
of LUTS in 20% of the patients, it was reported that
LUTS may also be associated with chronic prostatitis
(1). Nevertheless, chronic inflammation with BPH
is not necessarily symptomatic (3). According to
the National Institute of Health (NIH) classification,
category IV prostatitis is asymptomatic chronic
prostatitis defined by the presence of inflammatory
cells in expressed prostatic secretion or in histological
prostate specimens (5). NIH-IV prostatitis was
reported to be present in 43-98% of histological
specimens of resected prostates (6,7).
The goal of surgery for the management of LUTS
caused by BPH is to relieve the symptoms associated
with bladder outlet obstruction (BOO). Currently, the
gold standard therapy for the management of BOO
is transurethral resection of the prostate (TURP) (811). Although most patients benefit from the surgery
and experience relief from their symptoms, there
may be a substantial number of patients suffering
516

from continuing LUTS. Thus, satisfactory results
in the post-operative period cannot be obtained in
every patient. Continuing symptoms may be related
to the presence of preoperative prostatic infections,
especially NIH-IV prostatitis. In the present study,
we aimed to determine whether the simultaneous
presence of NIH-IV CP and BPH has any impact on
early post-operative symptoms following TURP.
Materials and methods
Between 2004 and 2008, medical records were
evaluated for 247 patients who underwent TURP
because of symptomatic BPH in Adana Numune
Training and Research Hospital. All of the patients
were treated by a single surgeon and the evaluation
of their files was performed retrospectively. Due to
the occurrence of an acute prostatitis episode within
6 months prior to TURP, 17 patients were excluded
from the study. Similarly, patients with prostate
cancer, stone disease, central and/or peripheral
neurologic dysfunction, or a previous history of
transurethral instrumentation were also excluded.
Patients were divided into 2 groups according to
histological diagnosis. Patients who had histological
diagnosis of only BPH were put in Group 1 whereas
Group 2 consisted of patients with both NIH-IV
CP and BPH. Factors such as total prostate specific
antigen (tPSA) levels, International Prostate
Symptom Scores (IPSS), single-question quality
of life (QoL) assessments, maximum flow rates
(Q max), residual urine volumes, catheterization
times, re-catheterization rates, and the duration of
re-catheterization were compared between these 2
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groups. IPSS, QoL, and uroflowmetry measurements
were compared between 2 groups once again at the
third post-operative month.
Statistical analysis was performed using Student’s
t-test and chi-square tests using SPSS® (version 16,
Chicago, USA).
Results
The mean ages of patients in Group 1 and 2 were
68.3 ± 4.0 (51-85) and 68.2 ± 3.0 (51-82), respectively.
There was no statistically significant difference (P >
0.05). Of the 230 patients, 29 (12.6%) were in Group
2.
One hundred patients (89.6%) had a history of use
of alpha adrenergic blocker therapy while 25 patients
in Group 2 (86.2%) reported to use alpha adrenergic
blockers preoperatively.

In Group 1, the mean IPSS, Q max, QoL, prostate
volume, and total prostate specific antigen (tPSA)
levels were 19.3 ± 6.6, 7.9 ± 3.3 mL/s, 5.6 ± 1.8, and
71.1 ± 14.0 mL. For those patients in Group 2 the
same numbers were determined at 19.1 ± 6.7, 7.8 ±
3.1 mL/s, 5.8 ± 2.0, and 68.0 ± 13.0 mL (P > 0.05). The
mean durations of catheterization time in Groups 1
and 2 were 3.2 ± 0.4 and 3.1 ± 0.3 days, respectively
(P > 0.05) (Table 1).
Within the first 24 h after removal of the Foley
catheter, 6 patients in Group 1 (2.9%) and 5 cases in
Group 2 (17.2%) underwent re-catheterization (P
< 0.05) (Table 1). Re-catheterization durations for
Groups 1 and 2 are shown in Table 1.
At the third post-operative month, Q max, IPSS,
and QoL figures in Group 1 and 2 were 17.2 ± 1.8
mL/s and 17.1 ± 1.6 (P > 0.05), 4.4 ± 0.4 and 6.2 ± 0.6
(P < 0.05), and 2.2 ± 2.0 and 3.8 ± 3.0, respectively (P
< 0.05) (Table 2).

Table 1. Comparison of preoperative values of BPH (Group 1) and BPH plus chronic prostatitis (Group 2).
Group 1

Group 2

P

201

29

Age (years)

68.3 ± 4.0

68.2 ± 3.0

> 0.05

tPSA (ng/mL)

3.6 ± 0.7

3.6 ± 0.9

> 0.05

IPSS

19.3 ± 6.6

19.1 ± 6.7

> 0.05

Q max (mL/s)

7.9 ± 3.3

7.8 ± 3.1

> 0.05

QoL

5.6 ± 1.8

5.8 ± 2.0

> 0.05

Prostate volume (mL)

71.1 ± 14.0

68.0 ± 13.0

> 0.05

Re-catheterization (%)

2.9

17.2

< 0.05

3.2 ± 0.4

3.1 ± 0.3

> 0.05

Preoperative
n

Re-catheterization duration (days)

Table 2. Comparison of post-operative values of BPH (Group 1) and BPH plus chronic prostatitis (Group 2).
Group 1

Group 2

P

Q max (mL/s)

17.2 ± 1.8

17.1 ± 1.6

> 0.05

IPSS

4.4 ± 0.4

6.2 ± 0.6

< 0.05

QoL

2.2 ± 2.0

3.8 ± 3.0

< 0.05

90th day post-operation
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Discussion
This study has shown that in the TURP treated
patients with symptomatic BPH, presence of NIH-IV
CP caused an increase in IPSS and re-catheterization
rates while it caused a decrease in QoL.
BPH is a histological diagnosis and defined as the
presence of stromal-glandular hyperplasia within
the prostate gland (1,12). The prevalence of BPH is
estimated to be around 42% for men between the
ages of 51 and 60; this figure reaches as high as 90%
for those 81 to 90 years of age (2,13). In fact, BPH was
reported to be as prevalent as diabetes mellitus and
hypertension in the aging male subgroup (14). BPH
is a progressive disease and the condition becomes
clinically relevant if it is associated with bothersome
LUTS such as urinary frequency, urgency, nocturnal
frequency, intermittency, decreased force of stream,
or the sensation of incomplete bladder emptying.
These symptoms are directly or indirectly caused by
the BOO, which is a result of the enlarged prostate
compressing the urethra (15). More than 50% of men
over 50 years of age experience LUTS secondary to
BPH (13).
Frequently, BPH and inflammation coexist.
Although the reported incidence of prostatitis in men
older than 40 years is reported to be 5%-10% (14), the
results from postoperative or postmortem histological
studies showed an incidence of inflammation ranging
from 30% to 78% in patients with BPH (16-18). Many
recent studies point out an association between BPH
and prostate inflammation. BPH tissues are rich in
chronic inflammatory infiltrates and hyperplastic
nodules (13,16-18). A direct correlation with early
onset of BPH-LUTS and young onset prostatitis
was found. At the same time, an inverse correlation
was reported between daily use of non-steroidal
anti-inflammatory drugs and the worsening of the
LUTS related to BPH (18-20). A Medical Therapy
of Prostatic Symptoms (MTOPS) trial indicated
that inflamed glands have larger volumes than noninflamed glands and predispose patients to a higher
rate of BPH-BOO related complications such as
acute urinary retention (20). A similar association
between inflammation and BPH symptom severity
was also reported in the Reduction by Dutasteride
of Prostate Cancer Events (REDUCE) trial (18,19).
Nickel et al. described glandular inflammation as
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the third and most important component in the
pathogenesis of BPH and development of LUTS.
This inflammation was suggested to combine both
the static (mechanical urethral obstruction) and the
dynamic (detrusor hypertrophy and bladder neck
smooth muscle failure) components of LUTS (21).
As an indirect sign of the association between BPH
and inflammation, C-reactive protein (CRP) levels
were measured in a previous study. CRP levels were
found to be above the limit of detection (>3.00 mg/L)
in patients with inflammation and patients with
elevated CRP levels were 1.47 times more likely to
have 3 or more symptoms than men with a C-reactive
protein concentration below the detection limit (22).
In our study, we did not demonstrate any
statistically significant difference in preoperative
IPSS, Q max, QoL, or tPSA parameters between the
2 groups (P > 0.05). Age and prostate volumes are the
2 most important factors which both independently
impact the parameters subject to BPH. Neither of
these parameters was statistically different between
the groups (P > 0.05).
At the third month following the surgery, IPSS
and QoL measurements showed a significant
difference between 2 groups (P < 0.05). We did not
find any significant difference with respect to Q max
levels. This result is not surprising since relieving the
obstruction ensures a better Q max in both groups.
However, IPSS and QoL figures measure different
aspects of patient satisfaction with the surgery.
Moreover, prostatitis symptoms are usually irritative
and continuing effects of prostatitis after surgery for
BPH might contribute to the presence of LUTS and
patient discomfort.
We determined that the re-catheterization ratio
was significantly higher in Group 2 patients when
compared to those from Group 1 (P < 0.05). This
may be explained by the earlier onset and longer
duration of BOO in patients with prostatitis. Another
explanation may be that the duration of inflammatory
answer was longer because of the underlying
inflammation in patients with prostatitis. Resolution
of the post-operative edema at the bladder neck may
last longer than expected because of this long-acting
inflammation.
The primary goal of treatment in patients with
symptomatic BPH is to relieve the symptoms
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associated with BOO. Although, TURP is the gold
standard and reference therapy for symptomatic
BPH (8-11), some patients do not benefit from the
procedure as expected and LUTS may continue after
the surgery. Recently, the MTOPS and REDUCE trials
have pointed out a possible association between the
inflammation of the prostate and LUTS. Prolonged
urinary retention and acute urinary retention were
also found to be predisposing conditions leading
to insufficient satisfaction rates after TURP surgery
(11). As mentioned previously, the early onset of
inflammation causes early onset BPH which may
lead to prolonged periods of retention. The MTOPS

trial reported a comparably high prevalence of acute
urinary retention in patients with BPH combined
with inflammation (20).
In the present study, NIH-IV CP was shown to
have deteriorating effects on the early post-operative
results of TURP surgery in patients treated for
symptomatic BPH. We believe that it would be useful
to review the post-operative expectations of both
surgeons and their patients that exhibit both BPH and
NIH-IV CP. However, further prospective controlled
studies with larger series are needed to effectively
document the role of prostatitis in symptomatic relief
after surgery for BPH.
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